Sustained effectiveness of pfizer-biontech and moderna vaccines against covid-19 associated hospitalizations among adults - united states, march-july 2021

Mark W. Tenforde, Wesley H. Self, Eric A. Naioti, Adit A. Ginde, David J. Douin, Samantha M. Olson, H. Keipp Talbot, Jonathan D. Casey, Nicholas M. Mohr, Anne Zepeski, Manjusha Gaglani, Tresa McNeal, Shekhar Ghamande, Nathan I. Shapiro, Kevin W. Gibbs, D. Clark Files, David N. Hager, Arber Shehu, Matthew E. Prekker, Heidi L. EricksonMichelle N. Gong, Amira Mohamed, Daniel J. Henning, Jay S. Steingrub, Ithan D. Peltan, Samuel M. Brown, Emily T. Martin, Arnold S. Monto, Akram Khan, Catherine L. Hough, Laurence W. Busse, Caitlin C. ten Lohuis, Abhijit Duggal, Jennifer G. Wilson, Alexandra June Gordon, Nida Qadir, Steven Y. Chang, Christopher Mallow, Carolina Rivas, Hilary M. Babcock, Jennie H. Kwon, Matthew C. Exline, Natasha Halasa, James D. Chappell, Adam S. Lauring, Carlos G. Grijalva, Todd W. Rice, Ian D. Jones, William B. Stubblefield, Adrienne Baughman, Kelsey N. Womack, Christopher J. Lindsell, Kimberly W. Hart, Yuwei Zhu, Meagan Stephenson, Stephanie J. Schrag, Miwako Kobayashi, Jennifer R. Verani, Manish M. Patel

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations

Abstract

In a multistate network that enrolled adults hospitalized during March-July 2021, effectiveness of 2 doses of mRNA vaccine against COVID-19-associated hospitalization was sustained over a follow-up period of 24 weeks (approximately 6 months). These findings of sustained VE were consistent among subgroups at highest risk for severe outcomes from COVID-19, including older adults, adults with three or more chronic medical conditions, and those with immunocompromising conditions. Overall VE in adults with immunocompromising conditions was lower than that in those without immunocompromising conditions but was sustained over time in both populations.

Original languageEnglish (US)
Pages (from-to)1156-1162
Number of pages7
JournalMorbidity and Mortality Weekly Report
Volume70
Issue number34
DOIs
StatePublished - Aug 2021
Externally publishedYes

ASJC Scopus subject areas

  • Epidemiology
  • Health(social science)
  • Health, Toxicology and Mutagenesis
  • Health Information Management

Fingerprint

Dive into the research topics of 'Sustained effectiveness of pfizer-biontech and moderna vaccines against covid-19 associated hospitalizations among adults - united states, march-july 2021'. Together they form a unique fingerprint.

Cite this